Research News and Research

RSS

Research suggests bevacizumab delays progression in newly diagnosed ovarian cancer

Early results from a large Phase-III trial suggest that adding bevacizumab to chemotherapy as a treatment for newly diagnosed ovarian cancer reduces the risk of disease progression during the first year of treatment. At the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy, Dr Tim Perren from Leeds Teaching Hospitals NHS Trust, UK, reported findings from the international ICON7 trial, which included 1528 women with high-risk early or advanced stage epithelial ovarian cancer, primary peritoneal cancer or Fallopian tube cancer.

11 Oct 2010

Embryonic stem cells used in first trial for spinal cord injury

The first ever patient to receive treatment in a U.S. government approved study involving human embryonic stem cells has been injected with millions of the potentially life saving cells. He is presently being treated at the Shepherd Center in Atlanta. He was partially paralyzed following a spinal cord injury. The center specializes in treating these types of injuries.

11 Oct 2010

Baby born from 20 year old frozen embryo

A 42 year old mother gave birth to a baby born from an embryo frozen 20 years ago. This is the longest time a fertilized egg has been stored before developing into a healthy baby, and could eventually lead to thousands of women having children in middle age feel experts.

11 Oct 2010

Atomic Tattoos launches 'Tats for Tatas' breast cancer awareness fundraising campaign

Atomic Tattoos has announced the launch of their "Tats for Tatas" fundraising campaign that will take place throughout October, benefiting the Florida Breast Cancer Foundation in Florida and Southeast Regional Breast Cancer Fund in Wisconsin. In the company's concerted efforts to raise awareness and funds for Breast Cancer Awareness, Atomic Tattoos is offering several specials throughout the month if customers donate $5 to breast cancer awareness.

11 Oct 2010

New technologies and surgical techniques promise 'personalized' orthopedic operations

A number of new technologies and surgical techniques promise to "personalize" orthopedic operations such as hip and knee replacement, according to research to be presented at an educational program at Hospital for Special Surgery on October 15 and 16. During "Computer Assisted Orthopaedic Surgery: Review of Emerging Technologies," prominent orthopedic researchers will discuss how innovative technologies can improve surgical outcomes.

11 Oct 2010

Merck Serono announces first results from Erbitux BALI-1 study in metastatic triple-negative breast cancer

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced the first results from the BALI-1 study of Erbitux® (cetuximab) in the treatment of metastatic triple-negative breast cancer (TNBC), an aggressive cancer in which early relapse and metastasis are common. The data, presented during the 35th Congress of the European Society for Medical Oncology (ESMO), demonstrate that Erbitux has the potential to improve outcomes for women with this relentlessly devastating cancer.

11 Oct 2010

Generex plans common stock rights offering

Generex Biotechnology Corporation today announced that it plans to initiate a rights offering of common stock and warrants to its existing stockholders in the event that the stockholders approve a reverse stock split at the reconvened special meeting of stockholders scheduled for 10 a.m. EDT on Friday, October 15, 2010.

11 Oct 2010

Obesity treatments falter, but researchers announce gene links

The Wall Street Journal: "An international research consortium says it has identified 18 new gene sites linked to obesity and 13 others associated with how fat is distributed in the body, advances that shed new light on the complex biology underlying one of the world's most pressing public-health problems. The findings are based on studies involving nearly 250,000 people, making the effort the largest so far to unravel the genetic basis of common human traits, researchers said.

11 Oct 2010

Health Robotics enters distribution agreements with Newico and Apta Medica for 7 new European countries

Health Robotics today announced that it recently signed exclusive distribution agreements for its CytoCare, i.v.STATION, and i.v.SOFT world-leading technologies in seven new European countries with regional industry leaders Newico and Apta Medica, rapidly continuing on its worldwide quest to pervasively provide safe and cost-effective Intravenous (IV) Admixture Compounding Automation to hospitals all over the world.

11 Oct 2010

Best defense against osteoporosis begins in childhood

While osteoporosis most typically affects persons over age 50, the best defense against it begins in childhood.

11 Oct 2010

ImaginAb and Imanet enter master service agreement for pre-clinical and clinical imaging

ImaginAb, Inc. and Imanet have signed a master service agreement for pre-clinical and clinical imaging. This agreement supports the development strategy for ImaginAb's pipeline of next generation diagnostic imaging agents based on recombinant antibody fragments. The Imanet™ network of Positron Emission Tomography (PET) imaging sites provides assistance in all aspects of PET imaging-based clinical trials: from proof-of-concept radiochemistry to clinical imaging, with more than 40 PET research tracers.

11 Oct 2010

New data on implementation of minimally invasive treatments for ruptured intracranial aneurysms

Two recent studies from the Zeenat Qureshi Stroke Research Center, in Minneapolis, MN, provide new data regarding implementation of minimally invasive treatments for ruptured intracranial aneurysms and impact on patient outcomes in U.S.

11 Oct 2010

Fat-free popcorn may help dieters maintain reduced calorie eating plans

ConAgra Foods, Inc., one of North America's leading food makers, announced today new research indicating that a daily snack of Orville Redenbacher's 94 percent fat-free SmartPop!® popcorn can help dieters maintain reduced calorie eating plans while still feeling full and satisfied. In the study, 94 percent of participants said the daily 100-calorie snack of 100 percent whole grain popcorn helped satisfy hunger and 85 percent credited SmartPop! with helping them stay on track with weight loss.

11 Oct 2010

Health care interests push to make ACOS pay off for them

Kaiser Health News staff writers Phil Galewitz and Jenny Gold write about increasing interest in the accountable care organizations that may come out of the new health overhaul.

11 Oct 2010

NCQA recertifies Lilly's online Health Education Answers program

Lilly's Health Education Answers program, an interactive online health and wellness tool, has received Health Information Product Recertification from the National Committee for Quality Assurance (NCQA).

11 Oct 2010

COU-AA-301 Phase 3 study demonstrates improvement in CRPC survival rate

Results from a pre-specified interim analysis of a randomized, placebo-controlled Phase 3 study, COU-AA-301, demonstrate that patients treated with the investigational agent abiraterone acetate plus low-dose prednisone/prednisolone showed a significant improvement in overall survival compared to patients treated with prednisone/prednisolone plus placebo.

11 Oct 2010

Varian and Stanford scientists receive $3.6M NIH grant to develop advanced imaging technology

Scientists from Stanford University and from the Ginzton Technology Center at Varian Medical Systems have jointly received a $3.6 million five-year research grant from the U.S. National Institutes of Health (NIH) to develop advanced imaging technology for improving the quality of CT images for patients with metal objects in their bodies such as hip implants and dental fillings.

11 Oct 2010

Sales of Merck's telcagepant and CoLucid's lasmiditan in world's major markets to reach $1.3 billion in 2019

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that two first-in-class agents — Merck's telcagepant and CoLucid's lasmiditan — will earn combined sales of approximately $1.3 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

11 Oct 2010

Arable introduces CTMS and EDC software for clinical organizations

Arable Corporation has announced the launch of Arable Perform to bring unique CTMS technologies to the clinical trial industry. Whereas traditional CTMS systems have been costly and require months to implement, Perform brings CTMS and EDC capabilities without the traditionally high start-up costs.

11 Oct 2010

TruTouch secures grant to accelerate development of next-generation technology platform

TruTouch Technologies, a pioneer in non-invasive biometric intoxication detection systems, today announced that it has secured a $438,000 grant to accelerate the development of its next-generation technology platform.

11 Oct 2010

Research News and Research

Research suggests bevacizumab delays progression in newly diagnosed ovarian cancer

Embryonic stem cells used in first trial for spinal cord injury

Baby born from 20 year old frozen embryo

Atomic Tattoos launches 'Tats for Tatas' breast cancer awareness fundraising campaign

New technologies and surgical techniques promise 'personalized' orthopedic operations

Merck Serono announces first results from Erbitux BALI-1 study in metastatic triple-negative breast cancer

Generex plans common stock rights offering

Obesity treatments falter, but researchers announce gene links

Health Robotics enters distribution agreements with Newico and Apta Medica for 7 new European countries

Best defense against osteoporosis begins in childhood

ImaginAb and Imanet enter master service agreement for pre-clinical and clinical imaging

New data on implementation of minimally invasive treatments for ruptured intracranial aneurysms

Fat-free popcorn may help dieters maintain reduced calorie eating plans

Health care interests push to make ACOS pay off for them

NCQA recertifies Lilly's online Health Education Answers program

COU-AA-301 Phase 3 study demonstrates improvement in CRPC survival rate

Varian and Stanford scientists receive $3.6M NIH grant to develop advanced imaging technology

Sales of Merck's telcagepant and CoLucid's lasmiditan in world's major markets to reach $1.3 billion in 2019

Arable introduces CTMS and EDC software for clinical organizations

TruTouch secures grant to accelerate development of next-generation technology platform

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Improving healthcare sustainability through carbon data